Urol. praxi. 2021;22(3):125-132 | DOI: 10.36290/uro.2021.017

The actual pharmacotherapy benign hyperplasia according to EAU Guidelines

MUDr. Aleš Horák
ANDROPHARM medical, s. r. o., Ostrava

Pharmacological treatment is the basis for conservative treatment of lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia (BPH). Currently, pharmacological treatment is based on α1-blockers, 5α-reductase inhibitors, muscarinic receptor antagonists, phosphodiesterase 5 inhibitors, beta-3 adrenoceptor agonists and a combination of some of them. In indicated cases, phytopharmaceuticals, most commonly containing Serenoa repens, may be used in patients with minor LUTS.

Keywords: benign prostatic hyperplasia, α1-blockers, 5α-reductase inhibitors, antagonists, muscarinic receptors, phosphodiesterase 5 inhibitors, beta-3 adrenoceptor, agonists, Serenoa repens.

Received: April 18, 2021; Revised: April 25, 2021; Accepted: April 25, 2021; Prepublished online: April 25, 2021; Published: October 21, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák A. The actual pharmacotherapy benign hyperplasia according to EAU Guidelines. Urol. praxi. 2021;22(3):125-132. doi: 10.36290/uro.2021.017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gravas S, Cornu J N, Gacci M, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO), https://uroweb.org/guideline/treatment-of - non-neurogenic-male-luts/.
    2. Klečka J, Běhounek P, Hora M. Význam kombinační terapie v léčbě symptomů dolních cest močových v souvislosti s benigní hyperplazií prostaty. Urol. praxi 2009; 10(3): 175-181.
    3. Djavan B, et al. Longitudinal study of men with mild symptoms of bladder outlet Obstruction treated with watchful waiting for four years. Urology 2004; 64: 1144. https://www.ncbi.nlm.nih.gov/pubmed/15596187. Go to original source... Go to PubMed...
    4. McConnell JD, et al. The long-term effect of doxazosin, finasteride, and combination therapy On the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387. https://www.ncbi.nlm.nih.gov/pubmed/14681504. Go to original source... Go to PubMed...
    5. Barendrecht MM, et al. Do alpha1-adrenoceptor antagonists improve lower urinary Tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn 2008; 27: 226. https://www.ncbi.nlm.nih.gov/pubmed/17638312. Go to original source... Go to PubMed...
    6. Djavan B, et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor Antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64: 1081. https://www.ncbi.nlm.nih.gov/pubmed/15596173. Go to original source... Go to PubMed...
    7. Michel MC, et al. Comparison of tamsulosin efficacy in subgroups of patients with lower Urinary tract symptoms. Prostate Cancer Prostatic Dis 1998; 1: 332. https://www.ncbi.nlm.nih.gov/pubmed/12496876. Go to original source... Go to PubMed...
    8. Roehrborn CG. Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 2006; 9: 121. https://www.ncbi.nlm.nih.gov/pubmed/16304557. Go to original source... Go to PubMed...
    9. Roehrborn CG, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2 - year results from the CombAT study. J Urol 2008; 179: 616. https://www.ncbi.nlm.nih.gov/pubmed/18082216. Go to original source... Go to PubMed...
    10. Roehrborn CG, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123. https://www.ncbi.nlm.nih.gov/pubmed/19825505. Go to original source... Go to PubMed...
    11. Karavitakis M, et al. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. Eur Urol 2019; 75: 788. https://www.ncbi.nlm.nih.gov/pubmed/30773327. Go to original source... Go to PubMed...
    12. Welk B, et al. The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist: a population based cohort study. BMJ 2015; 351: h5398. https://www.ncbi.nlm.nih.gov/pubmed/26502947. Go to original source... Go to PubMed...
    13. Van Dijk MM, et al. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 2006; 66: 287. https://www.ncbi.nlm.nih.gov/pubmed/16526818. Go to original source... Go to PubMed...
    14. Gacci M, et al. Impact of medical treatments for male lower urinary tract symptoms due to Benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med 2014; 11: 1554. https://www.ncbi.nlm.nih.gov/pubmed/24708055. Go to original source... Go to PubMed...
    15. Andriole G, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alphareductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172: 1399. https://www.ncbi.nlm.nih.gov/pubmed/15371854. Go to original source... Go to PubMed...
    16. Naslund MJ, et al. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for The enlarged prostate. Clin Ther 2007; 29: 17. https://www.ncbi.nlm.nih.gov/pubmed/17379044. Go to original source... Go to PubMed...
    17. McConnell JD, et al. The effect of finasteride on the risk of acute urinary retention and the Need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557. https://www.ncbi.nlm.nih.gov/pubmed/9475762. Go to original source... Go to PubMed...
    18. Nickel JC, et al. Comparison of dutasteride and finasteride for treating benign Prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011; 108: 388. https://www.ncbi.nlm.nih.gov/pubmed/21631695. Go to original source... Go to PubMed...
    19. Boyle P, et al. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia With finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398. https://www.ncbi.nlm.nih.gov/pubmed/8804493. Go to original source... Go to PubMed...
    20. Gittelman M, et al. Dutasteride improves objective and subjective disease measures in men With benign prostatic hyperplasia and modest or severe prostate enlargement. J Urol 2006; 176: 1045. https://www.ncbi.nlm.nih.gov/pubmed/16890688. Go to original source... Go to PubMed...
    21. Roehrborn CG, et al. Long-term sustained improvement in symptoms of benign Prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 2005; 96: 572. https://www.ncbi.nlm.nih.gov/pubmed/16104912. Go to original source... Go to PubMed...
    22. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008; 101(Suppl. 3): 17. https://www.ncbi.nlm.nih.gov/pubmed/18307681. Go to original source... Go to PubMed...
    23. Andriole GL, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010. 362: 1192. https://www.ncbi.nlm.nih.gov/pubmed/20357281. Go to original source... Go to PubMed...
    24. Thompson IM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215. https://www.ncbi.nlm.nih.gov/pubmed/12824459. Go to original source... Go to PubMed...
    25. Baldwin CM, et al. Transdermal oxybutynin. Drugs, 2009; 69: 327. https://www.ncbi.nlm.nih.gov/pubmed/19275276. Go to original source... Go to PubMed...
    26. Michel MC, et al. Does gender or age affect the efficacy and safety of tolterodine? J Urol 2002; 168: 1027. https://www.ncbi.nlm.nih.gov/pubmed/12187215. Go to original source... Go to PubMed...
    27. Hofner K, et al. Safety and efficacy of tolterodine extended release in men with overactive Bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol 2007; 25: 627. https://www.ncbi.nlm.nih.gov/pubmed/17906864. Go to original source... Go to PubMed...
    28. Kaplan SA, et al. Tolterodine extended release attenuates lower urinary tract symptoms in Men with benign prostatic hyperplasia. J Urol 2005; 174: 2273. https://www.ncbi.nlm.nih.gov/pubmed/16280803. Go to original source... Go to PubMed...
    29. Roehrborn CG, et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008; 72: 1061. https://www.ncbi.nlm.nih.gov/pubmed/18817961. Go to original source... Go to PubMed...
    30. Gacci M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61: 994. https://www.ncbi.nlm.nih.gov/pubmed/22405510. Go to original source... Go to PubMed...
    31. Wang Y, et al. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. Lower urinary tract symptoms 2018. 10: 84. https://www.ncbi.nlm.nih.gov/pubmed/293415. Go to original source... Go to PubMed...
    32. Porst H, et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract Symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology 2013; 82: 667. https://www.ncbi.nlm.nih.gov/pubmed/23876588. Go to original source... Go to PubMed...
    33. Casabe A, et al. Efficacy and safety of the coadministration of tadalafil once daily with Finasteride for 6 months in men with lower urinary tract symptoms and prostatic Enlargement secondary to benign prostatic hyperplasia. J Urol 2014; 191: 727. https://www.ncbi.nlm.nih.gov/pubmed/24096118. Go to original source... Go to PubMed...
    34. Andersson KE. On the Site and Mechanism of Action of beta3-Adrenoceptor Agonists in The Bladder. Int Neurourol J, 2017; 21: 6. https://www.ncbi.nlm.nih.gov/pubmed/28361520. Go to original source... Go to PubMed...
    35. Liao CH, et al. Mirabegron 25mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction. Urology 2018; 117: 115. https://www.ncbi.nlm.nih.gov/pubmed/29630956. Go to original source... Go to PubMed...
    36. Van Gelderen M, et al. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middleagedm to elderly men. International Journal of Clinical Pharmacology and Therapeutics 2014; 52: 693. https://www.ncbi.nlm.nih.gov/pubmed/24755125. Go to original source... Go to PubMed...
    37. Athanasopoulos A, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169: 2253. https://www.ncbi.nlm.nih.gov/pubmed/12771763. Go to original source... Go to PubMed...
    38. Roehrborn CG, et al. Efficacy and safety of a fixed-dose combination of dutasteride And tamsulosin treatment (Duodart((R)) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int 2015; 116: 450.https://www.ncbi.nlm.nih.gov/pubmed/25565364. Go to original source... Go to PubMed...
    39. Roehrborn CG, et al. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy In patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of The CombAT study. BJU Int 2014; 113: 623. https://www.ncbi.nlm.nih.gov/pubmed/24127818. Go to original source... Go to PubMed...
    40. Kaplan SA, et al. Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial. J Urol 2016; 195: 1825. https://www.ncbi.nlm.nih.gov/pubmed/26678956. Go to original source... Go to PubMed...
    41. Lee HN, et al. Rate and associated factors of solifenacin add-on after tamsulosin Monotherapy in men with voiding and storage lower urinary tract symptoms. International Journal of Clinical Practice 2015; 69: 444. https://www.ncbi.nlm.nih.gov/pubmed/25363606. Go to original source... Go to PubMed...
    42. Van Kerrebroeck P, et al. Combination therapy with solifenacin and tamsulosin oral Controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol 2013; 64: 1003. https://www.ncbi.nlm.nih.gov/pubmed/23932438. Go to original source... Go to PubMed...
    43. Athanasopoulos A, et al. The role of antimuscarinics in the management of men with Symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol 2011; 60: 94. https://www.ncbi.nlm.nih.gov/pubmed/21497434. Go to original source... Go to PubMed...
    44. Kaplan SA, et al. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract 2011; 65: 487. https://www.ncbi.nlm.nih.gov/pubmed/21210910. Go to original source... Go to PubMed...
    45. Kim HJ, et al. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker With an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. PLoS One 2017; 12: e0169248. https://www.ncbi.nlm.nih.gov/pubmed/28072862. Go to original source... Go to PubMed...
    46. Drake MJ, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: Results from the NEPTUNE study and NEPTUNE II open-label extension. Eur Urol 2015. 67: 262. https://www.ncbi.nlm.nih.gov/pubmed/25070148. Go to original source... Go to PubMed...
    47. Drake MJ, et al. Responder and health-related quality of life analyses in men with L ower Urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin OCAS: results from the NEPTUNE study. BJU Int 2016; 117: 165. https://www.ncbi.nlm.nih.gov/pubmed/25907003. Go to original source... Go to PubMed...
    48. Gong M, et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin 2015; 31: 1781. https://www.ncbi.nlm.nih.gov/pubmed/26211817. Go to original source... Go to PubMed...
    49. Kaplan SA, et al. Solifenacin plus tamsulosin combination treatment in men with lower urinary Tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 2013. 63: 158. https://www.ncbi.nlm.nih.gov/pubmed/22831853. Go to original source... Go to PubMed...
    50. Stárka L, Sosvorová L, Mikšátková P. Herbální přípravky používané při léčbě příznaků benigní hyperplazie prostaty. Urol. praxi 2012; 13(6): 244-246.
    51. Madersbacher S, et al. Plant extracts: sense or nonsense? Curr Opin Urol 2008; 18: 16. https://www.ncbi.nlm.nih.gov/pubmed/18090484. Go to original source... Go to PubMed...
    52. Kliment J, Horňák M, et al. Peparáty z rastlinných extraktov, In: Kliment J, Horňák M, et al. Benígna hyperplázia prostaty. Osveta, Martin 1996: 167-170. ISBN: 80-217-0343-1.
    53. De Monte C, et al. Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms. BMC Urol 2014; 14: 63. https://www.ncbi.nlm.nih.gov/pubmed/25112532. Go to original source... Go to PubMed...
    54. Slíva J. Serenoa repens v léčbě benigní hyperplazie prostaty. Urol. praxi 2017; 18(4): 165-168. Go to original source...
    55. Vávřová L. Účinky hexanového extraktu z palmy pilovité (Serenoa repens, Permixon® 160 mg, v ČR dostupný pod názvem Capistan®) na zánětlivé biomarkery v léčbě obtíží souvisejících s benigní hyperplazií prostaty. Urol. praxi 2016; 17(4): 192-194.
    56. European Medicines Agency Committee on Herbal Medicinal Products. European Union Herbal monograph on Serenoa repens (W. Bartram) Small, fructus. EMA/HMPC/280079/2013, 2015. https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbalmonograph-serenoa-repens-w-bartram-small-fructus_en.pdf.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.